Introducing PAX – PET ALLERGY XPLORER: The first molecular serum IGE test for pets
A GLOBAL PARTNERSHIP BETWEEN MADX AND NEXTUME REGARDING PET ALLERGY TESTING ON THE HIGHEST SCIENTIFIC LEVEL
Macro Array Diagnostics (MADx) is partnering with Nextmune to offer the first commercial serological IgE-specific test for pets based on molecular allergens: the Pet Allergy Xplorer, PAX in short.
Traditional allergy testing in veterinary medicine has not changed for decades and is based on placing allergen extracts on an enzyme linked immunoassay (ELISA). The issue with this method is that results can vary considerably depending on the extract, and false-negative results can occur frequently due to insufficient protein allergen concentrations.
PAX is based on revolutionary technology provided by MADx and Nextmune’s expertise in the fundamentals of companion animal allergology. The PAX uses allergen extracts and molecular components to identify allergens affecting pets and includes advantages such as improved reproducibility and cross-reactivity identification, improved accuracy, increased data (up to 300 results), improved treatment recommendations, and more. MADx CEO, Dr. Christian Harwanegg, states: “With PAX, we are finally able to not just provide accurate and reliable allergy diagnostics for human patients, but also their pet companions. Pet allergy diagnostics is a growing market, and we are excited to work together with a science-driven partner such as Nextmune to provide this innovative product in the field of veterinary medicine.”
Nextmune CEO, Magnus Kjellberg, adds: “We appreciate the development cooperation with MADx, and we are proud to walk this new path together. Nextmune is the only veterinary diagnostic laboratory currently using molecular allergology. We are convinced that this product will allow veterinarians to diagnose allergic pets more sensitively and accurately, which will benefit the animals and their keepers alike.”
PAX is now available for the testing of dog and horse sera, while the testing of other pet sera will be possible in the future. PAX is available for purchase directly from Nextmune (nextmune.com) and Nextmune’s partners around the globe.
ABOUT MADX:
Since the foundation of MADx in 2016, the company produces reliable allergy and food intolerance tests for laboratories, doctors' practices, hospitals, and allergy testing centres. MADx offers future-oriented, intuitive immunodiagnostic all-in-one solutions on a molecular basis. The company’s vision lies in digitising and cross-linking immunodiagnostic products and services to improve people’s quality of life, enabling individualised patient care, advancing science, and relieving the burden on the healthcare system. MADx is proud to be active in over 80 countries worldwide.
ABOUT NEXTMUNE:
Nextmune is a science-driven, global specialty pharma company dedicated to improving health for dogs, cats, and horses, focusing on allergy and dermatology as well as specialised care and nutrition. The product offering encompasses diagnostics, prescription and nonprescription products and is offered to veterinarians and pet parents in more than 70 countries worldwide.
FURTHER QUESTIONS AND CONTACT:
Mag. Karin Kernmayer-Farr
Head of Marketing & Communications
Macro Array Diagnostics GmbH
Lemböckgasse 59/Top 4
A-1230, Vienna
Tel.: +43 (0) 664 3981134
Mail: kernmayer@macroarraydx.com